Any week now, Australia will set its 2035 emissions target. It must signal the nation’s strong ambition on climate action, to drive policy and investment. And it must avoid being seen as either unrealistic or too costly. The decision is not an easy one for Prime Minister Anthony Albanese and his cabinet.
If any Australian government has had a clear runway for ambitious climate policy, it is this one. A successful first term, and a landslide win in an election partly fought over climate and energy policy, gives the Albanese government an opportunity for a lasting legacy.
But the tightrope the government must walk spans a wide gulf. The Climate Change Authority’s draft advice floated emissions reduction of 65-75% by 2035. Environment groups are gunning for the high end of the range; some business groups agree, but others won’t.
The challenge is formidable – but now is not a time for timidity on Australia’s climate policy.
A 65% target would mean halving Australia’s current emissions.Brook Mitchell/Getty Image
A huge task ahead
Under the Paris Agreement, Australia’s 2035 emissions target is due by the end of September.
Our 2030 target is a 43% emissions reduction, based on 2005 levels. Australia is far from reaching that goal. It can still be achieved, but quick, drastic change is needed.
Australia’s national emissions are at around 28% below 2005 levels. They fell 1.4% over the last year, to almost the same level as three years ago.
Any emissions reduction target of 60% or more for 2035 will be highly ambitious. It would require deep, rapid emissions cuts across the economy.
But it’s technically possible. And it’s desirable economically – to attract investment and position Australia for long-term success.
It’s all about follow-through
The main question is not precisely what 2035 target the government sets. Rather, it’s whether the government follows through – with stronger and extra policies – and if business will get on board.
Useful policies were enacted during the last term of government – for industry, renewables supply and cars. But these are tender beginnings compared to what’s needed.
An economy-wide carbon price at a sizeable level would be ideal. However, the eternally adverse politics under the “carbon tax” label seem to rule it out.
Instead, the government could deploy and calibrate a range of policies in all sectors to achieve a comparable effect. These include emissions markets, regulation, tax and subsidies.
The Productivity Commission has called for a nationally consistent emissions-reduction approach guided by a set of “national carbon values”, representing the implied carbon prices needed to meet Australia’s net-zero goals.
The higher the implied carbon price, the greater the incentive for businesses and others to reduce emissions. These benchmarks would be used by government to ensure efforts are efficient, coordinated and on-target.
Any implied carbon price would need to rise far beyond levels in Australia’s carbon credit markets – currently about A$30-40 per tonne of carbon dioxide.
Australia’s fuel excise, converted to carbon terms, is about $190 and rising. Infrastructure Australia, which now requires greenhouse gas emissions to be valued in project proposals, pegs the carbon value at more than $200 a tonne for the 2030s, and rising.
Clean energy gridlock
Old coal power plants are being replaced by wind, solar and energy storage. But progress in the clean energy transition is much slower than what’s needed.
The government’s underwriting scheme takes care of investor worries about low wholesale power prices in future, by guaranteeing a base level of revenue. But proposed power line and clean energy projects are stuck in the quicksand of objections and assessments.
State and federal governments must snap out of the business-as-usual approach to regulation and approval, which is not geared for rapid change.
The tightrope here is between jumping in to rebuild the power supply system as an urgent national priority, and bowing to fears and grumbles – some amplified by politicians – about higher electricity bills, power lines and wind turbines.
Balancing emissions and industry pain
For industry, the tightrope spans necessary modernisation on one side, and the risk of industrial closures on the other.
The Safeguard Mechanism encourages businesses to cut emissions, by requiring them to buy carbon credits if they exceed a certain limit. But the credit market prices are far too low to drive the required investment.
Reform is needed. It could mean tightening rules for carbon credits produced by projects that store carbon in the land sector. It might mean limiting industry’s use of carbon credits and increasing the rates of emissions reduction by each facility. Or it might involve setting a minimum price for carbon credits in the market, and increasing the maximum price.
Land sector lagging on climate action
In land use, forestry and agriculture, very little is being done to reduce emissions.
Much could and should be done. The current carbon credit scheme is inherently limited. Governments must get much more active.
That may mean buying marginal lands for conservation. It might mean regulating land use and forestry more actively, and combining biodiversity projects with carbon storage. It might also mean subsidising new green practices in agriculture.
The tightrope is between creating greener and more efficient land-based industries, and fears of leaving farmers and rural communities stranded.
Shifting gears on transport reform
The government’s new vehicle emissions standards will help make electric cars and smaller cars cheaper. But low-carbon transport policy is not all about the price of cars.
Australia urgently needs an extensive, reliable electric vehicle (EV) charging network, better urban public transport, and more and better rail lines. We should start using carbon-neutral aviation fuels, and charge carbon levies on jet fuel.
And mining and agricultural machinery must electrify and become more efficient. To that end, the fuel excise could ultimately be extended to all fuel use in the economy, covering also aviation, mining and agriculture.
The government’s mooted road user charge should be merely the beginning of reform in this area.
The challenge here is to do tax reform that can fund future public transport infrastructure, when there are many competing budget priorities.
A crossroads for Australia’s climate future
If things go well, Australia’s 2035 emissions target will be strong and broadly accepted as a desirable ambition by the community and by business. This will give a licence for much stronger emissions reduction policies across the economy, spurring investment and economic modernisation.
If things go badly, a strong political constellation for meaningful progress towards net zero emissions would be squandered.
Against the backdrop of Australia’s climate wars, most actions needed to meet an ambitious 2035 target will be seen as politically difficult. But now is the time for decisiveness in the nation’s long-term interest.
Frank Jotzo leads research projects on climate, energy and industry policy. He advises state governments including as a commissioner with the NSW Net Zero Commission and chair of the Queensland Clean Economy Expert Panel. He also led the Carbon Leakage Review for the federal government.
A dolphin tour operator is backing the state government’s new algal bloom tourism relief scheme, but says he will not benefit because the mammals have disappeared from his usual visiting sites.
Shoppers in England bought 437m carrier bags last year as online food shops replace supermarket trips
Plastic bag sales have risen for the first time in 10 years on the back of the so-called Ocado effect as online food shops and ultra-fast deliveries replace supermarket trips.
Shoppers in England bought 437m single-use plastic carrier bags last year, compared with 407m the year before, a rise of 7%, according to data from Department for Environment, Food and Rural Affairs.
Last month, Australia’s ban on the import, use and manufacture of three types of “forever chemical” came into effect. These chemicals – PFOA, PFOS and PFHxS – have long lifespans and resist breaking down. They’re considered harmful due to their ability to build up inside living organisms and their toxicity. In 2023, the World Health Organization’s cancer agency declared PFOA to be a human carcinogen (cancer-causing agent), and PFOS a potential carcinogen.
But these three chemicals are just a drop in the ocean. There are now more than 14,000 types of forever chemicals, known formally as per- and poly-fluoroalkyl chemicals, or PFAS for short. In response to public concern, the European Union has proposed to restrict all types of PFAS by 2030.
Australia’s ban on the three most concerning chemicals is positive. But it’s slow. Authorities wait until new evidence of harm emerges for specific chemicals. This risk-based approach leaves the door wide open for thousands of other PFAS chemicals – and all other industrial chemicals being developed at the staggering rate of 1.4 per second.
When it comes to PFAS, caution is wise
Since the 1950s, PFAS chemicals have been widely used in industrial products due to their usefulness in making products nonstick or resistant to water or fire.
The problem is, these forever chemicals are highly persistent. There’s little ability to reverse harm from exposure.
Some of these chemicals may not be harmful. But they often haven’t been tested to find out. This is why the EU is using the precautionary principle: if in doubt, act cautiously to avoid potentially large harms. A total ban would avoid “regrettable substitution”, where banned chemicals are quickly replaced by a slightly different variant.
To date, the most severely affected communities and workers are those at or near chemical production plants, military sites, airports and other sites where PFAS-laced firefighting foam is used.
Since then, concern has broadened out to the much lower levels commonly found in drinking water, food, food packaging, cookware, carpets and air.
Control efforts have been slow
The 2001 Stockholm Convention on Persistent Organic Pollutants took aim at 12 industrial chemicals known to be toxic and persistent. In 2004, Australia ratified the convention and moved to control these chemicals.
No PFAS chemicals were in this first group. But over time, the convention was amended to phase out the forever chemicals PFHxS and PFOA and restrict PFAS.
Australia didn’t use the Stockholm Convention to ban these three chemicals. That’s because the government hasn’t completed work on a domestic treaty allowing it to ratify the amendments.
In recent years, public concern has centred on PFAS levels in drinking water. Australia’s expert health panel concluded there was limited to no evidence linking the PFAS group of chemicals to clinically significant harm. The panel stated the limited evidence available on cancer relates to PFOA, not the PFOS chemical used more commonly in Australia.
By contrast, peak bodies in the United States and Europe found some of these chemicals are linked to health issues such as lower birth weights, higher cholesterol, reduced kidney function, thyroid disease and several cancers.
Firefighting foams often use PFAS chemicals, leading to major pollution in some sites.Jana Shea/Getty
If in doubt, act with caution
One of the clearest definitions of the precautionary principle is in the 1992 Rio Declaration on Environment and Development, which states:
where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation.
To make the wholesale PFAS phase-out successful, the EU’s chemical agency is consulting with manufacturers and users on how the chemicals are used and whether safer alternatives exist. Promising alternatives have been identified.
At present, manufacturers have most information about toxicity, while regulators are tasked with protecting the public and the environment without necessarily having enough data. In these cases, it makes sense to adopt the precautionary principle.
Forever chemicals will have a long legacy even if they are banned. Any ban should be accompanied by work defining acceptable levels of PFAS chemicals as a class in water, soil, air and food.
The case for a wider Australian ban
Most PFAS chemicals are imported into Australia. This means PFAS pollution can be handled largely by regulating imports of PFAS-containing products.
For products without an alternative or those essential to, say, healthcare, more research will be needed to eliminate the most risky compounds.
Any move towards a large-scale ban in Australia will incur a manufacturer backlash, as has happened in Europe.
But there’s a clear incentive for policymakers to act. At present, cleaning up PFAS contamination is inevitably paid for by taxpayers – and this cost will only grow. Regulating chemicals such as PFAS based on their individual risk is no longer fit for purpose.
By November 2025, Australia’s Senate committee on PFAS will file its report.
The committee could do a lot worse than looking to the European precautionary plan to ban the whole group of chemicals, while keeping in mind essential use. It would be sensible to permit new chemicals to be used only if they’re safe enough.
Bhavna Middha receives funding from the Australian Research Council through the Discovery Early Career Research Award( ARC DECRA)
Ralph Horne receives funding from The Australian Research Council as a Chief Investigator on the TREMS Research Hub (Industrial Transformation Research Hub for Transformation of Reclaimed Waste Resources to Engineered Materials and Solutions for a Circular Economy)
Vincent Pettigrove receives funding from various water authorities and other governmental agencies, notably the Aquatic Pollution Prevention Partnership with Melbourne Water.
When your dog starts limping or your cat comes down with a sniffle, it’s natural to worry. For many families, pets are more than just animals – and we want them to have a standard of medical care similar to our own.
But it can still be surprising when the vet prescribes a medication that looks identical to something in your own bathroom cabinet.
Many human medicines are safe and effective for pets when used under veterinary guidance. But others can be harmful due to differences in how animals process drugs. So sometimes, pets need their own medicines.
So let’s examine the differences between drugs for humans and animals – and why you shouldn’t just give a pet your own medications.
In Australia, the Therapeutic Goods Administration approves and regulates drugs for humans. The Australian Pesticides and Veterinary Medicines Authority APVMA does the same for pet drugs.
While both agencies consider efficacy and safety in deciding whether to approve a product, the APVMA also considers environmental impact. For example, medicines given to animals – especially when given at scale on farms – can leach into waterways, affecting aquatic life and water quality.
The market for animal medicines is smaller than that for humans, making them less cost-effective to develop. Sometimes, no medicine exists for an animal condition and vets may need to use a human medicine.
For certain diseases and conditions, vets are legally permitted to dispense human medicines for pets through a process called off-label prescribing.
There are also medicines approved for both humans and pets. They include classes of antibiotics, antidepressants, corticosteriods (anti-inflammatory drugs), antiparasitics and chemotherapy drugs.
For example, doxorubicin is a chemotherapy drug used in humans to treat cancers including those of the lungs and bone. In dogs, it is commonly used to treat lymphomas, melanomas and cancers of the bone, among others. In both humans and dogs, doxorubicin is used to treat mammary gland (breast) cancer.
Similarly, ivermectin can be used to treat parasite infections such as scabies in humans and animals.
While many drugs are shared between humans and pets, not all are safe. In fact, some common household medications can badly harm or kill animals.
The painkillers ibuprofen and paracetamol are toxic to both dogs and cats. They can cause damage to the animal’s stomach and kidneys, and may kill them.
This is because dogs and cats break down medicines different to the human body. For example, the proteins in a cat’s liver are different from the human liver, so they can’t break down paracetamol. It can damage their red blood cells and reduce their body’s ability to carry oxygen.
And the situation can differ between animals. The flea and tick medication permethrin, for instance, is safe for dogs but highly toxic to cats – potentially causing tremors, seizures and death.
And pets are far more sensitive to drug dosages than humans, so even small quantities of the wrong medicine can be fatal.
Pets may also be given medicines no longer used for humans, or one specifically developed for animals.
Carprofen is a non-steroidal anti-inflammatory drug previously used in humans but is now only prescribed for dogs. A vet might prescribe it for pain or inflammation.
We don’t use it in humans anymore because it’s expensive to manufacture. But it’s still used for dogs because it’s effective, and alternatives such as paracetamol and ibuprofen aren’t suitable for them.
Typically, medicines are developed for pets only when they address a condition specific to animals.
For example, humans don’t usually suffer from heartworm, but infection in pets is common. The arsenic-based drug melarsomine was designed specifically for animals and treats heartworm in adult dogs.
If your pet is sick or injured, never give them a drug out of your own medicine cabinet – even if the vet has previously prescribed them the medication.
Take your animal to the vet. They will advise on the most appropriate treatment and dose, so you don’t do your pet further harm.
Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance. He is a fellow of the Royal Australian Chemical Institute. Nial is the chief scientific officer of Vaihea Skincare LLC, a director of SetDose Pty Ltd (a medical device company) and was previously a Standards Australia panel member for sunscreen agents. He is a member of the Haleon Australia Pty Ltd Pain Advisory Board. Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design and testing.